Researchers have developed an innovative antivenom using antibodies from a hyperimmune individual, showing potential effectiveness against venom from some of the world's most dangerous snakes. This advancement comes in light of the significant health risks posed by snake bites, which result in approximately 137,000 fatalities annually and many more cases of disability and amputation.
Current antivenom treatments are typically derived from antibodies produced in sheep or horses and are tailored to specific snake species. This method, while effective, can lead to severe allergic reactions and requires accurate identification of the snake species involved in the bite. In contrast, the new approach aims to create a universal antivenom by targeting broadly neutralizing antibodies that could work against multiple venomous snakes.
The research led by Jacob Glanville from Centivax in California involved locating an individual who had been exposed to snake venom multiple times. Tim Friede, known for self-administering escalating doses of venom from various snake species, was identified as a suitable candidate. The team extracted 40 milliliters of blood from Friede, creating a library of billions of antibodies. Testing revealed that two specific antibodies, LNX-D09 and SNX-B03, along with a toxin inhibitor called varespladib, provided full protection against 13 snake species, including several types of cobras and the common taipan.
Next steps involve further testing on animals treated for snake bites in veterinary clinics. Researchers, including Tian Du from the University of Sydney, express optimism about the potential for a universal treatment, while also seeking to understand whether the new antivenom can prevent tissue necrosis associated with severe snake envenomations.